SydesMRSpiegelhalterDJAltmanDGBabikerABParmarMK. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials2004; 1: 60–79.
3.
SydesMRAltmanDGBabikerABParmarMKSpiegelhalterDJ. Reported use of data monitoring committees in the main published reports of randomized controlled trials: A cross-sectional study. Clin Trials2004; 1: 48–59.
4.
KiriATonasciaSMeinertCL. Treatment effects monitoring committees and early stopping in large clinical trials. Clin Trials2004; 1: 40–47.
5.
DawsonL. The Salk Polio Vaccine Trial of 1954: Risks, randomization and public involvement in research. Clin Trials2004; 1: 122–30.
6.
BurkeDS. Lessons learned from the 1954 Field Trial of Poliomyelitis Vaccine. Clin Trials2004; 1: 3–5.
7.
CarinoTSheingoldSTunisS. Using clinical trials as a condition of coverage: Lessons from the National Emphysema Treatment Trial. Clin Trials2004; 1: 108–14.
8.
MarksHM. A conversation with Paul Meier. Clin Trials2004; 1: 131–38.
9.
GoodmanSNRosnerDReverbySMChalmersIRosenbergCE. Harry Marks: An appreciation. Clin Trials2011; 8: 123–27.
10.
YusufSBoschJDevereausPJ. Sensible guidelines for the conduct of large randomized trials. Clin Trials2008; 5: 38–39.
11.
BiswasSLiuDDLeeJJBerryDA. Bayesian clinical trials at the University of Texas M.D. Anderson Cancer Center. Clin Trials2009; 6: 205–16.
12.
HernanMAHernandez-DiazS. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials2012; 9: 48–55.
13.
ShrierISteeleRJVerhagenE. Beyond intention to treat: What is the right question?Clin Trials. Epub ahead of print 3 October 2013. DOI: 10.1177/1740774513504151.
14.
FordJGHowertonM. The science of recruiting minority populations to screening trials. Clin Trials2004; 1: 341–42.
15.
FordMEHavstadSLDavisSD. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials2004; 1: 343–51.
16.
BastianH. Consumer and researcher collaboration in trials: Filling the gaps. Clin Trials2005; 2: 3–4.
17.
LangstonALMcCallumMCampbellMKRobertsonCRalstonSH. An integrated approach to consumer representation and involvement in a multicentre randomized controlled trial. Clin Trials2005; 2: 80–87.
18.
DickersinKDavisBRDixonDO. The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clin Trials2004; 1: 417–20.
19.
MagnusDCaplanAL. Risk, consent, and SUPPORT. N Engl J Med2013; 368: 1864–65.
20.
DrazenJMSolomonCGGreeneMF. Informed consent and SUPPORT. N Engl J Med2013; 368: 1929–31.
21.
CohenMSMcCauleyMSugarmanJ. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: An ethical odyssey. Clin Trials2012; 9: 340–47.
22.
MillerFG. Clinical equipoise and risk-benefit assessment. Clin Trials2012; 9: 621–27.
23.
FergussonDGlassKHuttonBShapiroS. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding?Clin Trials2005; 2: 218–29.
PogueJSackettDL. Clinician-trialist rounds: 19. Faux pas or fraud? Identifying centers that have fabricated their data in your multi-center trial. Clin Trials. Epub ahead of print 3 October 2013. DOI: 10.1177/1740774513503524.
26.
AndersonGLKooperbergCGellerN. Monitoring and reporting of the Women’s Health Initiative randomized hormone therapy trials. Clin Trials2007; 4: 207–17.
27.
WittesJBarrett-ConnorEBraunwaldE. Monitoring the randomized trials of the Women’s Health Initiative: The experience of the Data and Safety Monitoring Board. Clin Trials2007; 4: 218–34.
28.
GoodmanSN. Rashomon revisited: Two views of monitoring the Women’s Health Initiative trials. Clin Trials2007; 4: 205–06.
